A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

References

Page 1

	Year	Citations
Nonparametric Estimation from Incomplete Observations Edward L. Kaplan, Paul Meier Journal of the American Statistical Association EngineeringAgingLife PredictionRare Event EstimationMortality Rates	1958	38.7K
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL C. J. Clopper, E. S. Pearson Biometrika ReliabilityC. J. ClopperStatistical ReviewBehavioral SciencesConfidence Distributions	1934	4.6K
Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results Joyce O’Shaughnessy, David Miles, Svetislava J. Vukelja, Journal of Clinical Oncology	2002	1.1K
Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer Joanne L. Blum, Stephen E. Jones, Aman U. Buzdar, Journal of Clinical Oncology	1999	787
Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine Edith A. Perez, Guillermo Lerzo, Xavier Pivot, Journal of Clinical Oncology	2007	392
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer Eva Thomas, Josep Tabernero, Monica Fornier, Journal of Clinical Oncology	2007	290
Phase II to III Study Comparing Doxorubicin and Docetaxel With Fluorouracil, Doxorubicin, and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre M. Bontenbal, Geert‐Jan Creemers, Hans J. Braun, Journal of Clinical Oncology	2005	102
Impact of chemotherapy beyond the first line in patients with metastatic breast cancer Armelle Dufresne, Xavier Pivot, Christophe Tournigand, Breast Cancer Research and Treatment Metastatic Breast CancerOncologyBreast OncologyFirst LineCancer Management	2007	79
Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane Carolien H. Smorenburg, M. Bontenbal, C. Seynaeve, Breast Cancer Research and Treatment UrologyMetastatic Breast CancerBreast OncologyMedicinePhase Ii Study	2001	73

Page 1